The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth.
作者信息
Frasca Joseph D, Cheifetz Adam S
机构信息
Univeristy of Vermont Medical Center, Burlington, VT, USA.
Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S388. doi: 10.21037/atm.2019.12.86.
Abstract
摘要
相似文献
1
The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth.从人群角度看抗TNF治疗的成本与效益——无论其价值如何。
Ann Transl Med. 2019 Dec;7(Suppl 8):S388. doi: 10.21037/atm.2019.12.86.
2
If it's not worth doing, it's not worth doing well.若不值得做，就不值得做好。
Pediatrics. 2005 Jan;115(1):196; author reply 196-7. doi: 10.1542/peds.2004-1971.
3
PET scanning: worth the cost in cancer? Not for all cancers--it's not reliable enough yet.
Oncology (Williston Park). 2014 May;28(5):391-2.
4
Calculating what it's worth. Value analysis pros making mark in healthcare.计算其价值。价值分析专家在医疗保健领域崭露头角。
Mod Healthc. 2005 Jul 11;35(27):28.
5
Are You Ready for Maintenance of Certification Self-Assessment 2.0?: It's Here, It's Cheaper, and It's Easier.你准备好迎接认证自我评估2.0的维护了吗？它来了，更便宜，也更简单。
JAMA Dermatol. 2016 May 1;152(5):515-6. doi: 10.1001/jamadermatol.2016.0877.
6
It's not easy being us, but it's worth it!做我们可不简单，但这值得！
Dent Today. 2002 Feb;21(2):14-7.
7
Outcomes research: Integrating PROs into the clinic - overall survival benefit or not, it's worth the trouble.结局研究：将患者报告结局纳入临床——无论是否有总体生存获益，这样做都值得。
Nat Rev Clin Oncol. 2017 Sep;14(9):529-530. doi: 10.1038/nrclinonc.2017.109. Epub 2017 Jul 18.
8
The last taboo. It's not sex. It's not drinking. It's stress--and it's soaring.最后的禁忌。不是性。不是饮酒。是压力——而且压力正在飙升。
Fortune. 2002 Oct 28;146(8):136-8, 140, 142 passim.
9
Just because it's low cost doesn't mean it's accessible.仅仅因为成本低并不意味着它易于获取。
J Gen Intern Med. 2012 Oct;27(10):1233-4. doi: 10.1007/s11606-012-2151-0.
10
Margaret McCartney: If screening is worth doing, it's worth doing well.玛格丽特·麦卡特尼：如果筛查值得去做，那就值得做好。
BMJ. 2018 Jul 9;362:k2986. doi: 10.1136/bmj.k2986.
本文引用的文献
1
Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease.在克罗恩病患者中，完全内镜愈合比部分内镜愈合的结局更好。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2256-2261. doi: 10.1016/j.cgh.2019.11.025. Epub 2019 Nov 16.
2
Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.生物制剂在炎症性肠病患者中的使用模式及非持续性和转换的预测因素：一项全国性基于人群的研究。
Dig Dis Sci. 2020 May;65(5):1436-1444. doi: 10.1007/s10620-019-05867-1. Epub 2019 Nov 1.
3
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.美国中重度溃疡性结肠炎患者中先进疗法的真实世界疗效
Inflamm Bowel Dis. 2020 May 12;26(6):941-948. doi: 10.1093/ibd/izz204.
4
Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?
Gastroenterology. 2019 Oct;157(4):922-924. doi: 10.1053/j.gastro.2019.08.001. Epub 2019 Aug 7.
5
Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.炎症性肠病患儿肿瘤坏死因子拮抗剂的利用趋势：一项加拿大基于人群的研究。
Inflamm Bowel Dis. 2020 Jan 1;26(1):134-138. doi: 10.1093/ibd/izz157.
6
Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure.无论之前是否接触过肿瘤坏死因子，戈利木单抗治疗溃疡性结肠炎的真实世界疗效
J Can Assoc Gastroenterol. 2018 Sep;1(3):129-134. doi: 10.1093/jcag/gwy019. Epub 2018 May 10.
7
Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.抗 TNF 治疗的引入并未使炎症性肠病的住院率和肠切除术率如预期般下降：一项基于人群的中断时间序列研究。
Gut. 2020 Feb;69(2):274-282. doi: 10.1136/gutjnl-2019-318440. Epub 2019 Jun 12.
8
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.与反应性监测相比，阿达木单抗浓度的主动监测与克罗恩病患儿的临床缓解增加相关。
Gastroenterology. 2019 Oct;157(4):985-996.e2. doi: 10.1053/j.gastro.2019.06.003. Epub 2019 Jun 10.
9
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.真实世界中炎症性肠病患者的生物制剂使用模式：治疗持久性、转换及同时应用免疫抑制治疗的重要性。
Inflamm Bowel Dis. 2019 Jul 17;25(8):1417-1427. doi: 10.1093/ibd/izz001.
10
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.在一项基于人群的队列研究中，与单药治疗相比，未接受过生物制剂治疗的患者采用 upfront 联合治疗与炎症性肠病相关并发症风险降低相关。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1788-1798.e2. doi: 10.1016/j.cgh.2018.11.003. Epub 2018 Nov 15.
Zotero 插件